A Multi-centered, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
Latest Information Update: 03 Jan 2025
At a glance
- Drugs SHR-1703 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Guangdong Hengrui Pharmaceutical
Most Recent Events
- 30 Dec 2025 Planned number of patients changed from 360 to 400.
- 30 Dec 2024 Status changed from not yet recruiting to recruiting.
- 25 Oct 2024 New trial record